Melanotan II.
Cyclic α-MSH analogue — pigmentation and sexual arousal pathways.
Build your bag, then either book a consultation (an EU-licensed physician reviews your file — anything declined is refunded) or upload an existing Rx at checkout.
- ✓Magistral preparation — Directive 2001/83/EC Art. 5(1).
- ✓Patient-named prescription only — dispensed against a valid Rx.
- ✓EU-GMP Annex 1 Grade A/B cleanroom compounding.
- ✓Cold-chain shipping across EU/EEA — 2–5 working days.
About Melanotan II.
Melanotan II is a cyclic α-MSH analogue with stronger and broader melanocortin-receptor activity than Melanotan I. It activates MC1R (pigmentation), MC4R (sexual arousal, appetite) and other MC receptors.
The broad activity gives it side effects (nausea, blood-pressure shifts) that require physician monitoring. Used for both pigmentation and sexual-arousal protocols.
Melanotan II is a cyclic heptapeptide agonist of MC1R, MC3R, MC4R and MC5R. The cyclic structure improves receptor binding and resistance to enzymatic degradation. Sexual-arousal effects come primarily through MC4R activation.
Subcutaneous injection, typically 0.25–0.5 mg per day during loading, then maintenance.
Your physician sets the prescription. This is descriptive information, not a self-administration guide.
Lyophilised: store at 2–8 °C, protect from light. Once reconstituted: 2–8 °C, use within 30 days. Do not freeze.
- INN / Name
- Melanotan II
- Form
- Lyophilised vial · subcutaneous injection
- Strength
- 10mg vial
- Manufacturing
- EU-GMP Annex 1 · Grade A/B
- Endotoxins
- European Pharmacopoeia 2.6.14 · LAL assay
- Identity & purity
- HPLC + MS · > 98%
- Cold chain
- Validated 2–8 °C, monitored end-to-end
- Regulatory basis
- Directive 2001/83/EC · Article 5(1)
2–5 working days
EU / EEA cold-chain delivery, 2–8 °C monitored end-to-end with digital temperature log. Tracking link sent on dispatch.
Magistral preparation
Patient-named preparation under Directive 2001/83/EC Article 5(1). Dispensed exclusively against a valid EU prescription.
EU prescription recognition
Prescriptions written in one EU member state are recognised in others under Directive 2011/24/EU on cross-border healthcare.